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Background: Macrovesicular steatosis is assumed to be an important risk factor for early allograft
dysfunction (EAD) after orthotopic liver transplantation (OLT).
Aim: To evaluate the impact of steatosis in combination with other risk factors on the outcome of OLT.
Methods: The degree of steatosis was analysed in 165 consecutive OLTs and was classified by
histological examination as non (M0), mild (<30%, M1), moderate (30–60%, M2) or severe steatosis
(>60%, M3). Recipients were analysed for EAD.
Results: EAD was observed in 28% of patients with M0, 26% with M1, 53% with M2 and 73% with M3
(P < 0.001). Patients with EAD had a significantly shorter graft survival after liver transplantation (P = 0.005)
but did not correlate with survival. In multivariate regression analysis, the grade of steatosis, donating
after cardiocirculatory death (DCD) grafts and duration of cold ischaemia time were significantly associ-
ated with EAD (P < 0.001, P = 0.01 and P = 0.001, respectively).
Conclusion: Livers with severe (M3) steatosis from DCD donors, combined with a prolonged CIT have
a high risk for developing EAD which is correlated with shorter graft survival. Therefore M3 livers should
only be considered for OLT in selected recipients without the presence of additional risk factors.
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Introduction
The increasing waiting list mortality in orthotopic liver trans-
plantation (OLT) as a result of ongoing organ shortage has led to
the use of organs from extended criteria donors, including
those with hepatic steatosis or non-alcoholic fatty liver disease
(NAFLD). Steatosis is considered to be one of the most impor-
tant variables in multivariate analysis of factors determining
graft function after transplantation.1 The presence of steatosis
is correlated with the development of primary non-function or
early allograft dysfunction (EAD).2,3 Marsman et al. propagate
discarding livers with more than 30% fatty infiltration owing to
the potential for EAD.4
Although several centres report encouraging results after
OLT with even severely fatty infiltrated livers, studies have
not been unanimous in their conclusions about the impact
of steatosis on the outcomes after liver transplantation.5–19
Some centres claim that fatty infiltrated livers should not be
considered for liver transplantation,1,4,13,15 whereas others state
that severely steatotic livers can be transplanted safely in selected
cases.5,6,12,14,18,19
The difference in point of view is reflected in the outcomes of a
survey determining acceptance policy. Only 6% would accept an
over 60% fatty infiltrated liver in the United States whereas 42%
would do so in the United Kingdom.20
There are multiple reports suggesting that livers with microve-
sicular steatosis have a better outcome after OLT compared with
livers with macrovesicular steatosis.10,21 The aim of the present
study was to evaluate the impact of donor hepatic steatosis on
graft function and survival after liver transplantation.
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Materials and methods
Data were analysed on consecutive patients who underwent
a cadaveric liver transplantation between January 2000 and
December 2004. Information was extracted from a prospectively
designed database which was updated with post-operative data
until August 2010.
Histological examination
The presence, type and severity of steatosis were determined in all
grafts. Steatosis was evaluated by biopsies at three standardised
time points at the end of cold ischaemia, immediately after rep-
erfusion and after 1 h of reperfusion. The grade of liver macro-
vesicular steatosis was determined according to international
standards:1,7,18
• M0: no macrovesicular steatosis,
• M1: mild focal macrovesicular steatosis (<30% hepatocytes
involved),
• M2: moderate, zonal macrovesicular steatosis (30% < 60%
hepatocytes involved) and
• M3: severe, panlobular macrovesicular steatosis (>60% hepato-
cytes involved).
All microscopic hematoxylin and eosin (H&E)-stained sections
were evaluated by two pathologists in a double-blinded fashion.As
the presence of microvesicular steatosis has not been reported to
adversely affect graft function, this was not captured separately.10
Clinical outcomes
To assess the degree of liver damage after liver transplantation, the
latest validated definition of early allograft dysfunction (EAD)22
was used: the incidence of EAD was determined when one or
more of the following criteria were met: (i) bilirubin >10 mg/dl on
post-operative day 7, (ii) international normalised ratio (INR) 
1.6 on post-operative day 7 and (iii) aspartate aminotransferase
(AST) or alanine transaminase (ALT) > 2000 IU/ml within the
first post-operative week.
The influence of the pre-operative situation on outcome after
transplantation was measured using the model of end-stage liver
disease (MELD) score.23 Cold ischemic time (CIT) was measured
to determine its influence on outcome after transplantation.
The total hospital length of stay (LOS) was calculated as time
admitted to the intensive care unit (ICU) and time admitted to the
clinical ward (CW) after transplantation.
Statistical analysis
Data were analysed with the Student’s t-test, chi-squared test,
Fisher’s exact test, ANOVA table’s and Spearman’s correlation
tests. Survival curves were analysed using the Kaplan–Meier
method and compared with the log-rank test. Logistic univariate
analysis and Cox regression were performed with all relevant base-
line factors: MELD score, level of steatosis, length of CIT and
donation after cardiocirculatory death (DCD). Influence on EAD,
graft survival (GS) and overall survival (OS) was expressed in
odds ratios and hazard ratios, respectively. Multivariate analysis
was executed with variables reaching a level of 10% significance in
univariate analysis. A stepwise back algorithm to exclude factors
without a predictive value was used at a level of 5% significance.
Results
Patient population
The study group consisted of 185 consecutive cadaveric liver trans-
plantation patients, 80 (43.2%) of whomwere female. Themedian
age of the patients was 48 years (mean 46, range 16–69). The donor
population had a median age of 47 years (mean 44, range 11–68).
Eight patients were not analysed as a result of intra-operative
death. There were four transplants with a primary non-function,
two with a M0 liver and two with a M3 liver. One of the M0 livers
was retrieved from a DCD donor. One patient died before a
re-transplantation could be performed, all others underwent a
re-transplantation. Critical pre-operative data or donor liver data
were missing in eight cases. As a result, data for 165 patients were
left for analysis of which 17 cases (10%) were re-transplants. The
median follow-up was 86 months (mean 75, range 0–127).
Prevalence of steatosis
The donor livers revealed M0 in 92 cases (55.8%), M1 in 39 cases
(23.6%), M2 in 19 cases (11.5%) and M3 in 15 cases (9.1%)
(Table 2). There was no significant difference in age, MELD score,
body mass index (BMI) and pre-operative creatinine between the
recipients in those groups based on the level of steatosis (Table 1).
The underlying disease of those receiving a M3 liver was primary
sclerosing cholangitis in four cases (26.7%), cyptogenic cirrhosis
in three cases (20.0%), idiopathic acute liver failure in three cases
(20.0%), hepatitis B in four cases (26.7%) and hepatitis C in one
case (6.7%).
Post-operative AST and ALT values
ALT values during the first post-operative week were significantly
higher when M3 livers were transplanted. The mean difference
was significant from the day of transplantation (P < 0.001)
through the sixth post-operative day (P = 0.022). Only the day of
transplantation (P = 0.010) and the fourth (P = 0.007) and the
fifth (P = 0.005) post-operative day showed significant different
AST values when stratified for steatosis. Towards the end of the
first week after transplantation, AST and ALT values return to
comparable levels for all types of donor livers (Fig. 1).
Prevalence of EAD
Fifty-seven patients (34.5%) were diagnosed with EAD (Table 2).
The prevalence of EAD after transplantation was significant
higher when donor livers with moderate (M2) or severe (M3)
steatosis were used (P = 0.039 and P < 0.001, respectively). As
expected, recipients of M1 livers performed as well as those of M0
livers (P = 0.759). Additionally, in univariate analysis both CIT
and DCD impacted EAD significantly (Table 3). DCD reached
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significance in spite of its low prevalence (n = 13). The EAD rate
within the DCD group was 63% compared with 39% for those
receiving a non-DCD liver. The mean CIT in the DCD group was
8.4 h compared with 7.2 h for the non-DCD group (P = 0.13).
Two patients received a M3 DCD liver; one did not experience
EAD, whereas the other did develop EAD and died 15 days post-
operatively as a result of multi-organ failure. All DCD grafts uti-
lised came from controlled, Maastricht classification III and IV,
donors. Severe steatosis remains a highly significant prognostic
baseline factor for the prevalence of EAD. After multivariate
analysis macrovesicular steatosis, DCD and CIT remain signifi-
cant (Table 4).
Graft survival
Five-year graft survival was 87.4% (SE  2.7%). Twenty out of
165 liver transplantations required re-transplantation (12.1%).
Three patients underwent multiple re-transplantations (2–3).
There was no significant difference in GS between steatotic livers
and non-steatotic livers (P = 0.38), as can be seen in the Kaplan–
Meier curve (Fig. 2). Patients experiencing EAD had a 5-year
Table 1 Patient characteristics and biochemical profile stratified for severe steatosis
Normal livers (<60%) Sever steatotic livers (60%) P
Patient characteristics
Age 46.0  1.05* 48.4  2.57* 0.490
Gender (M) 84 (56.0%) 11 (73.3%) 0.195
BMI 24.9  0.40* 24.0  0.51* 0.498
Diabetes 13 (8.7%) 0 0.611
Malignancy 13 (8.7%) 2 (13.3%) 0.630
Biochemical profile
Bilirubine 175.8  19.37* 183.3  51.81* 0.905
INR 2.26  0.14* 2.13  0.27* 0.781
Creatinine 91.4  5.71* 75.1  10.90* 0.370
MELD 17.9  0.99* 17.5  2.80* 0.889
Underlying disease
Hepatitis B 29 (19.3%) 4 (26.7%) 0.409
Hepatitis C 22 (14.7%) 1 (6.7%)
Alcoholic cirrhosis 12 (8.0%) 0
Cryptogenic cirrhosis 17 (11.3%) 3 (20%)
PSC 16 (10.7%) 4 (26.7%)
PBC 12 (8%) 0
Autoimmune hepatitis 13 (8.7%) 0
Idio. Or iatr. Acute liver failure 20 (13.3%) 3 (20%)
Other 9 (6%) 0
*Mean  SEM.
BMI, body mass index; iatr, iatrogenic; Idio, idiopathic; INR, international normalised ratio; MELD, model of end-stage liver disease; PBC, primary
billiary cirrhosis; PSC, primary sclerosing cholangitis.
Table 2 Results after transplantation
M0 M1 M2 M3 Total
n 92 (55.8%) 39 (23.6%) 19 (11.5%) 15 (9.1%) 165 (100%)
EAD
EAD 26 (28.3%) 10 (25.6%) 10 (52.6%) 11 (73.3%) 57 (34.5%)
No EAD 66 (71.7%) 29 (74.4%) 9 (47.4%) 4 (26.7%) 108 (65.5%)
P-value 0.759 0.039 0.001 0.001
LOS
ICU (median) 4 5 5 6 5
CW (median) 19 19 19 16 19
ICU, intensive care unit; LOS, hospital length of stay.
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Figure 1 First week post-operative values of aminotransferase (AST) and alanine transaminase (ALT). *P < 0.05
Table 3 Univariate analysis of prognostic factors for EAD, GS and OS
Variable EAD
OR (P)
95% CI GS
HR (P)
95% CI OS
HR (P)
95% CI
Meld score 1.03 1.00–1.06 1.03 0.99–1.06 0.99 0.97–1.02
(0.081) (0.120) (0.651)
Steatosis M0* 1 1 1
M1 0.88 0.37–2.05 0.48 0.14–1.64 1.44 0.74–2.78
(0.759) (0.240) (0.284)
M2 2.82 1.03–7.73 0.33 0.04–2.46 1.19 0.49–2.92
(0.044) (0.277) (0.703)
M3 6.98 2.04–23.91 0.42 0.06–3.19 1.32 0.50–3.46
(<0.001) (0.402) (0.572)
Cold ischemic time In hours 1.21 1.07–1.37 1.07 0.91–1.25 1.07 0.97–1.19
(0.003) (0.417) (0.193)
DCD No* 1 1 1
Yes 3.36 1.05–10.82 2.44 0.71–8.36 1.19 0.43–3.30
(0.042) (0.155) (0.744)
Liver injury No EAD* NA 1 1
EAD NA 3.26 1.33–7.99 1.19 0.67–2.13
(0.010) (0.557)
*Index.
DCD, donating after cardiocirculatory death; EAD, early allograft dysfunction; GS, graft survival; HR, hazard ratio; NA, not applicable; OR, odds ratio;
OS, overall survival.
Table 4 Multivariate analysis for liver dysfunction (EAD)
Variable n Haz ratio P 95% CI
Steatosis M0 92 1
M1 39 0.99 0.978 0.40–2.43
M2 19 3.59 0.021 1.21–10.62
M3 15 8.40 0.001 2.29–30.81
Cold ischemic time in hours 1.27 0.001 1.10–1.46
DCD No 152 1
Yes 13 5.67 0.011 1.50–21.44
CI, confidence interval; DCD, donating after cardiocirculatory death; HR, hazard ratio.
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Figure 2 (a) Graft survival vs. macro vesicular steatosis. (b) Graft survival vs. early allograft dysfunction
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GS of 76.4% whereas patients without EAD had a 5-year GS of
92.8% (P = 0.006, Fig. 2). In univariate analysis no additional
significant prognostic baseline factors for GS were identified.
As most graft loss was in the first 6 months, a subanalysis was
performed of this group. Aside from age no other patient or
disease characteristics with a prognostic value for early graft loss
were identified. Furthermore, M3 livers were not overrepresented
in this early graft loss group (Table 5). Six patients (42.9%) lost
their graft early as a result of billiary duct ischaemia, five (35.7%)
owing to hepatic artery thrombosis, two (14.3%) related to small-
for-size graft function and one related to chronic rejection (7.1%).
Patient survival
Overall actuarial 1-, 5- and 10-year patient survival rates were
84.8% (SE 2.8%) 75.0% (SE 3.4%) and 67.2% (SE 4.4%),
respectively. Patients withM0 livers had 78.1% 5-year OS, whereas
patients with M3 livers showed 66.7% 5-year OS. In spite of this
seemingly substantial difference in survival rates, significance was
not achieved (P = 0.732, Fig. 3), probably related to the low preva-
lence of M3 donor livers and subsequent type two error. Patients
with EAD after transplantation showed no significant difference
in survival rates, 70.0% vs. 77.7% (P = 0.552, Fig. 3). In univariate
analysis no significant factors influencing OS after transplantation
could be identified.
Hospital length of stay
The median hospital admission time after liver transplantation
was 24 days; the median ICU and ward stays were 5 and 19 days,
respectively (Table 2). There was no significant difference between
Table 5 Sub analysis early graft loss
Early graftloss
(within 6 months)
n = 14
No or late
graft loss
n = 151
P
Patient characteristics
Age 38.8  2.85* 47.0  1.02* 0.019
Gender (M) 6 (42.9%) 89 (58.9%) 0.244
BMI 24.1  2.29* 24.9  0.36* 0.590
Diabetes 0 13 (8.6%) 0.605
Malignancy 0 15 (9.9%) 0.368
Biochemical profile
Bilirubine 257.2  76.83* 169.4  18.54* 0.187
INR 2.32  0.40* 2.24  0.14* 0.859
Creatinine 72.7  9.54* 91.2  5.65* 0.354
MELD 18.9  3.10* 17.8  0.97* 0.734
Underlying disease
Hepatitis B 2 (14.3%) 31 (20.5%) 0.743
Hepatitis C 1 (7.1%) 22 (14.6%)
Alcoholic cirrhosis 0 12 (7.9%)
Cryptogenic cirrhosis 1 (7.1%) 19 (12.6%)
PSC 3 (21.4%) 17 (11.3%)
PBC 2 (14.3%) 10 (6.6%)
Autoimmune hepatitis 1 (7.1%) 12 (7.9%)
Idio. Or iatr. acute liver failure 3 (21.4%) 20 (13.2%)
Other 1 (7.1%) 8 (5.3%)
Steatosis
M0 9 (64.3%) 83 (55.0%) 1.00
M1 3 (21.4%) 36 (23.8%)
M2 1 (7.1%) 18 (11.9%)
M3 1 (7.1%) 14 (9.3%)
Peri-operative blood loss
Packed cells administered 6.3  0.67 7.3  0.50 0.543
*Mean  SEM.
BMI, body mass index; iatr, iatrogenic; Idio, idiopathic; INR, international normalised ratio; MELD, model of end-stage liver disease; PBC, primary
billiary cirrhosis; PSC, primary sclerosing cholangitis.
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Figure 3 (a) Survival vs. macro vesicular steatosis. (b) Graft survival vs. early allograft dysfunction
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mean LOS for patients with a steatotic donor liver compared with
a M0 liver [P = 0.383 (ICU)/P = 0.258 (CW)].
The median LOS for patients with EAD was 27 days; patients
without EAD were admitted for 23 days (Table 1). This mean
difference was not significant [P = 0.326 (ICU)/P = 0.178(ward)]
even when corrected for in-hospital deaths after transplantation.
Discussion
The widespread shortage of donor organs has led to a more
liberal acceptance of donor livers for transplantation with more
centres transplanting severely steatotic livers.5,6,12,14,18,19 A strong
association between macrovesicular steatosis and early allograft
dysfunction or even primary non-function has been described
previously.1,4,5,7–9,11,12,15,18,19
The present study confirms the correlation between severe
steatosis and early allograft dysfunction after transplantation.
Although severity of steatosis did not correlate with graft or
patient survival, the positive predictive value of EAD for shorter
graft survival was significant. EAD was not correlated with sur-
vival which is in contrast with earlier reported results by Olthoff
et al.22 who found a relative risk of 10.7% for death in the case
of EAD.
The accuracy of pre-transplant frozen sections has been
the subject of much debate for a number of years. Recently,
Allesandro et al.24 reported that pre-transplant frozen sections
were reliable when a cut-off point of 60% of steatosis was used
whereas it became less accurate when a cut-off point of 30%
was used.
In our series we noticed a prevalence of 28% of EAD in the M0
group, which is comparable with the M1 livers. This percentage
seems high when compared with other studies with a similar study
design. Afonso et al. reported a prevalence of initially poor func-
tion of the graft after transplantation of 22%,5 whereas this preva-
lence was as low as 9% in a study reported by Canello et al. The
lower prevalence in Canello’s study can be related to overlap with
M1 livers, in which the prevalence of initially poor function was as
high as 44%.8 It is difficult to report on these differences as the
present study included additional variables in the analysis such as
ischaemia time and DCD.
Recipients of M3 livers had amore complicated recovery period
in the first months after transplantation reflected in the fact that
they developed significantly more EAD which is correlated with
significantly more graft loss in the first post-operative months.
However, after approximately 6 months, they had the same prog-
nosis as patients without EAD. Therefore, based on this study we
cannot recommend that M3 livers should be discarded routinely.
As has frequently been described in the literature, other risk
factors should also be taken into account when considering the
suitability of a liver for transplantation. An important risk factor
associated with a less favourable outcome after transplantation
is using livers fromDCDdonors.The use of such livers is correlated
with an increased prevalence of primary non-function, a higher
re-transplantation rate and shorter graft and overall patient
survival.25–30 In the present study,DCDwas correlated significantly
with EAD and remained significant in multivariate analysis.
Other known risk factors for poor outcome after liver trans-
plantation are prolonged cold and warm ischaemic times. Pro-
longed CIT is strongly associated with poor graft function after
transplantation and a high prevalence of graft loss, particularly
when the graft was harvested from a DCD donor.28 In addition,
warm ischaemia times need to be minimised, preferably to less
than 30 min.27 Our results were in concordance with these studies.
In our series, severe steatosis, a DCD liver and a prolonged CIT
were significant in multivariate analysis and therefore all these
variables contribute to the prevalence of EAD. It is evident there-
fore, that care should be taken when M3 livers are transplanted,
especially in the presence of other risk factors such as DCD livers
and prolonged CIT.
Although beyond the scope of the present study, recipient
characteristics are probably equally important when deciding if
an organ is suitable for transplantation. Hepatitis C (HCV) is
increasingly recognised as one of the major causes leading to
end-stage liver failure and transplantation. Steatosis of the graft is
associated with viral recurrence.31 Although mildly steatotic livers
have no impact onHCV recurrence after transplantation,32 a com-
bination of severe fatty livers with prolonged CIT appears to have
a negative effect on graft survival.33
In conclusion, based on our data, steatotic livers, including
severely (>60%) steatotic livers, should not be routinely discarded
as they are in most transplant centres. Those livers could be used
in selected patients typically underserved by the current MELD
system, for instant in patients with a relatively long preserved liver
function such as primary sclerosing cholangitis (PSC). Avoiding
additional risk factors such as a prolonged CIT and livers from
DCD donors, these livers can be transplanted successfully.
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